IO Biotech, Inc. (NASDAQ:IOBT - Free Report) - Equities research analysts at HC Wainwright boosted their Q2 2025 earnings per share (EPS) estimates for IO Biotech in a research note issued to investors on Wednesday, May 14th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.38) per share for the quarter, up from their previous forecast of ($0.51). HC Wainwright currently has a "Buy" rating and a $12.00 target price on the stock. The consensus estimate for IO Biotech's current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for IO Biotech's Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.37) EPS, FY2026 earnings at ($1.01) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at ($0.25) EPS and FY2029 earnings at $0.03 EPS.
Separately, Piper Sandler raised IO Biotech to a "strong-buy" rating in a research note on Wednesday, March 12th.
Get Our Latest Report on IOBT
IO Biotech Price Performance
IO Biotech stock opened at $0.98 on Monday. The business has a 50 day moving average of $0.97 and a 200-day moving average of $0.93. IO Biotech has a 1 year low of $0.66 and a 1 year high of $1.73. The company has a market capitalization of $64.56 million, a P/E ratio of -0.72 and a beta of 0.09.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in IOBT. Dauntless Investment Group LLC acquired a new stake in IO Biotech during the 4th quarter valued at approximately $688,000. Landscape Capital Management L.L.C. acquired a new stake in IO Biotech during the 4th quarter valued at approximately $407,000. Citadel Advisors LLC acquired a new stake in IO Biotech during the 4th quarter valued at approximately $249,000. Renaissance Technologies LLC increased its position in IO Biotech by 22.5% during the 4th quarter. Renaissance Technologies LLC now owns 118,800 shares of the company's stock valued at $109,000 after purchasing an additional 21,800 shares during the period. Finally, XTX Topco Ltd increased its position in IO Biotech by 80.0% during the 1st quarter. XTX Topco Ltd now owns 50,486 shares of the company's stock valued at $55,000 after purchasing an additional 22,446 shares during the period. Institutional investors and hedge funds own 54.76% of the company's stock.
About IO Biotech
(
Get Free Report)
IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IO Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IO Biotech wasn't on the list.
While IO Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
